Inhibition	inhibition	O	O	O	O
of	of	O	O	O	O
immunoreactive	immunoreactive	O	O	O	O
corticotropin-releasing	corticotropin-releasing	O	O	O	O
factor	factor	O	O	O	O
secretion	secretion	O	O	O	O
into	into	O	O	O	O
the	the	O	O	O	O
hypophysial-portal	hypophysial-portal	O	O	O	O
circulation	circulation	O	O	O	O
by	by	O	O	O	O
delayed	delayed	O	O	O	O
glucocorticoid	glucocorticoid	O	O	O	O
feedback	feedback	O	O	O	O
.	.	O	O	O	O

Nitroprusside-induced	nitroprusside-induced	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
evokes	evokes	O	O	O	O
ACTH	acth	O	O	OTHERS	I
secretion	secretion	O	O	O	O
which	which	O	O	O	O
is	is	O	O	O	O
primarily	primarily	O	O	O	O
mediated	mediated	O	O	O	O
by	by	O	O	O	O
enhanced	enhanced	O	O	O	O
secretion	secretion	O	O	O	O
of	of	O	O	O	O
immunoreactive	immunoreactive	O	O	O	O
corticotropin-releasing	corticotropin-releasing	O	O	O	O
factor	factor	O	O	O	O
(	(	O	O	O	O
irCRF	ircrf	O	O	O	O
)	)	O	O	O	O
into	into	O	O	O	O
the	the	O	O	O	O
hypophysial-portal	hypophysial-portal	O	O	O	O
circulation	circulation	O	O	O	O
.	.	O	O	O	O

Portal	portal	O	O	O	O
plasma	plasma	O	O	O	O
concentrations	concentrations	O	O	O	O
of	of	O	O	O	O
neither	neither	O	O	O	O
arginine	arginine	CHEMICALS	O	OTHERS	I
vasopressin	vasopressin	CHEMICALS	O	OTHERS	I
nor	nor	O	O	O	O
oxytocin	oxytocin	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
significantly	significantly	O	O	O	O
altered	altered	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
paradigm	paradigm	O	O	O	O
.	.	O	O	O	O

Application	application	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
delayed	delayed	O	O	O	O
feedback	feedback	O	O	O	O
signal	signal	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
form	form	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
2-h	2-h	O	O	O	O
systemic	systemic	O	O	O	O
corticosterone	corticosterone	CHEMICALS	O	OTHERS	I
infusion	infusion	O	O	O	O
in	in	O	O	O	O
urethane-anesthetized	urethane-anesthetized	O	O	O	O
rats	rats	O	O	O	O
with	with	O	O	O	O
pharmacological	pharmacological	O	O	O	O
blockade	blockade	O	O	O	O
of	of	O	O	O	O
glucocorticoid	glucocorticoid	O	O	O	O
synthesis	synthesis	O	O	O	O
,	,	O	O	O	O
is	is	O	O	O	O
without	without	O	O	O	O
effect	effect	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
resting	resting	O	O	O	O
secretion	secretion	O	O	O	O
of	of	O	O	O	O
arginine	arginine	CHEMICALS	O	OTHERS	I
vasopressin	vasopressin	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
oxytocin	oxytocin	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
any	any	O	O	O	O
corticosterone	corticosterone	CHEMICALS	O	OTHERS	I
feedback	feedback	O	O	O	O
dose	dose	O	O	O	O
tested	tested	O	O	O	O
.	.	O	O	O	O

Resting	resting	O	O	O	O
irCRF	ircrf	O	O	O	O
levels	levels	O	O	O	O
are	are	O	O	O	O
suppressed	suppressed	O	O	O	O
only	only	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
highest	highest	O	O	O	O
corticosterone	corticosterone	CHEMICALS	O	OTHERS	I
infusion	infusion	O	O	O	O
rate	rate	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
resulted	resulted	O	O	O	O
in	in	O	O	O	O
systemic	systemic	O	O	O	O
corticosterone	corticosterone	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
of	of	O	O	O	O
40	40	O	O	O	O
micrograms/dl	micrograms/dl	O	O	O	O
.	.	O	O	O	O

Suppression	suppression	O	O	O	O
of	of	O	O	O	O
irCRF	ircrf	O	O	O	O
secretion	secretion	O	O	O	O
in	in	O	O	O	O
response	response	O	O	O	O
to	to	O	O	O	O
nitroprusside-induced	nitroprusside-induced	O	O	O	O
hypotension	hypotension	O	DISEASE	OTHERS	I
is	is	O	O	O	O
observed	observed	O	O	O	O
and	and	O	O	O	O
occurs	occurs	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
plasma	plasma	O	O	O	O
corticosterone	corticosterone	CHEMICALS	O	OTHERS	I
level	level	O	O	O	O
between	between	O	O	O	O
8	8	O	O	O	O
-	-	O	O	O	O
12	12	O	O	O	O
micrograms/dl	micrograms/dl	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
studies	studies	O	O	O	O
provide	provide	O	O	O	O
further	further	O	O	O	O
evidence	evidence	O	O	O	O
for	for	O	O	O	O
a	a	O	O	O	O
strong	strong	O	O	O	O
central	central	O	O	O	O
component	component	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
delayed	delayed	O	O	O	O
feedback	feedback	O	O	O	O
process	process	O	O	O	O
which	which	O	O	O	O
is	is	O	O	O	O
mediated	mediated	O	O	O	O
by	by	O	O	O	O
modulation	modulation	O	O	O	O
of	of	O	O	O	O
irCRF	ircrf	O	O	O	O
release	release	O	O	O	O
.	.	O	O	O	O

